central serous chorioretinopathy CSC
Conditions
Interventions
cCSC patients will be treated with Pred Forte® (PF®) eye drops or with placebo
eye drops 3 times a day for 4 weeks
Sponsors
Radboud Universitair Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Diagnosis of severe chronic central serous chorioretinopathy that meets the criteria outlined in section 6.1 of protocol - 18 years or older - doesn*t meet any exclusion criteria, is willing to sign the consent form - able to self-administer eye drops.
Exclusion criteria
Exclusion criteria: - evidence of another retinal diagnoses, such as exudative age-related macular degeneration, suspicion of secondary choroidal neovascularization, polypoidal choroidal vasculopathy, multifocal choroiditis, retinal vascular occlusions, pseudoxanthoma elasticum, amblyopia, and severe myopia (more than *6 dioptres). - women that are breast feeding or pregnant
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To investigate whether PF® topical eye drops lead to a reduction of intraretinal and subretinal fluid after 4 weeks in comparison to placebo eye drops. Treatment response is objectified by OCT | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints in this study are changes in best-corrected visual acuity and changes on multimodal imaging. | — |
Countries
Netherlands
Outcome results
None listed